Aspera Biomedicines, Inc.

This early-stage study is testing a new drug called rebecsinib in patients with two types of advanced blood cancers: secondary acute myeloid leukemia that has returned or not responded to treatment, and higher-risk myelofibrosis. The main goals are to find the safest dose and see…